The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, yet its legacy within the broader sector now raises questions about potential returns . Copycat versions are undercutting patent protection , prompting concerns that betting on companies significantly dependent to Viagra's previous position could be a dangerou… Read More